Hepan (Heparin Sodium, Dexpanthenol)

Hepan is used in clinical practice to manage and prevent thrombotic conditions while also supporting local tissue healing at the injection site.

• Anticoagulation for prevention of venous thromboembolism in at‑risk patients
• Treatment of acute deep‑vein thrombosis and pulmonary embolism
• Prophylaxis of clot formation after surgical procedures
• Adjunct therapy to maintain catheter patency
• Support of wound‑healing processes due to dexpanthenol content

Side effects associated with Hepan can vary in frequency and severity. Patients should be informed about both common and serious reactions.

Common

• Mild pain, redness, or bruising at the injection site
• Minor bleeding or hematoma formation
• Transient itching or rash near the administration area
• Slight increase in bleeding time during routine procedures

Serious

• Heparin‑induced thrombocytopenia (HIT) with potential for new clots
• Major or uncontrolled bleeding events
• Severe allergic reactions such as anaphylaxis
• Skin necrosis or ulceration at injection sites
• Paradoxical thrombosis despite anticoagulation

When prescribing or administering Hepan, healthcare professionals should consider several safety measures to minimize risk.

• Assess patient’s bleeding risk and review recent surgeries or trauma
• Monitor platelet counts regularly to detect possible HIT
• Avoid use in patients with active uncontrolled bleeding
• Use caution in renal or hepatic impairment, adjusting therapy as needed
• Consider age‑related dosing adjustments for elderly patients
• Review concomitant use of other anticoagulants or antiplatelet agents
• Pregnancy status is not well defined; evaluate benefits versus risks

Hepan may interact with other medications that affect hemostasis or platelet function. Awareness of these interactions helps prevent adverse events.

Avoid

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants)
• Antiplatelet drugs such as aspirin, clopidogrel, or ticagrelor
• Thrombolytic agents and fibrinolytics
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk

Use with caution

• Hormonal contraceptives or estrogen therapy
• Certain antibiotics (e.g., vancomycin) that may potentiate thrombocytopenia
• Chemotherapy agents that affect platelet production
• Corticosteroids that can alter coagulation parameters
• Vitamin K antagonists requiring close INR monitoring